Prevalence, With Medical Imaging, of the Parenchymatous and/or Ductal Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 200
- Locations
- 16
- Primary Endpoint
- Number of patients for whom the MRI and/or the echo endoscopy has shown a parenchymatous or ductal pancreatic anomaly
Study Overview
Brief Summary
Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is increasing both in France and in Europe, whereas all the other cancers are decreasing in Europe. Moreover, its seriousness is still high, with a mortality rate higher than the average incidence. The aim of PAPAFA study is to assess the prevalence of the pancreatic anomalies which can be revealed thanks to imaging, for patients having a 1st degree pancreatic adenocarcinoma familial history. This could allow detection of lesions which are less than 10 mm long, and improve the dark prognostic of this pathology.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •patients with a 1st degree familial history of pancreas adenocarcinoma
- •patients older than 40
- •patients whose life expectancy is > 3 months
- •inform and consent form signed
- •patient insured under the French social security system
Exclusion Criteria
- •contraindication to the MRI (pace-maker, implanted metallic material, medical history of allergy to the contrast agent, end-stage renal failure, pregnancy, claustrophobia)
- •contraindication to anesthesia to do the echo endoscopy
- •1st degree family history of 2 pancreas adenocarinomas
- •medical history of allergy to benzylic alcool
- •contraindication to dimeglumine gadobenate
- •pregnant or breastfeeding woman, according to the questioning
- •subjets who don't have the legal capacity to consent
Outcomes
Primary Outcomes
Number of patients for whom the MRI and/or the echo endoscopy has shown a parenchymatous or ductal pancreatic anomaly
Time Frame: six months after the last inclusion
For every patients who will have a pancreatic MRI detecting an anomaly, the echo endoscopy will be done. A cytology of the lesion from the echo endoscopy will be done for the solid lesions and for the indetermined cystic lesions (that is to say, the lesions which don't meet the literature set criteria for serous kyst or intraductal papillary and mucinous tumor of the pancreas) ; which is usually done in health care.
Secondary Outcomes
- Number of patients for whom the MRI has brought to light a parenchymatous and/or ductal pancreatic anomaly(six months after the last inclusion)
- Number of patients for whom the echo endoscopy has brought to light a parenchymatous and/or ductal pancreatic anomaly(six months after the last inclusion)
- Height of the lesions(six months after the last inclusion)
- Correlation between the data from the MRI and those from the echo endoscopy(six months after the last inclusion)
- Localisation of the lesions(six months after the last inclusion)
- Number of lesions(six months after the last inclusion)
- Aspect of the lesion (solid and/or liquid)(six months after the last inclusion)